Lhasa Limited

shared knowledge shared progress

ABOUT US |
CONTACT US |
CAREERS |
Login

Related News

Lhasa Limited release new data to AI/PDE project users
New PDE data is released into the AI/PDE database.
23 September 2021
Lhasa Limited releases new data to it's Nitrites in Excipients project users
04 June 2021
Lhasa Limited releases new data into its Intermediates Database
25 May 2021

Related Blog Articles

20 tips for nitrosamine impurity assessment
Many readers will be aware of the risk posed by nitrosamine impurities, as an ongoing pharmaceutical industry hot topic. In July 2021 ANVISA published their guidance for assessment and control of potentially carcinogenic nitrosamines in active pharmaceutical ingredients and drug products. To discuss this topic, we invited knowledgeable speakers from ANVISA, Industry - GSK and Libbs Farmacêutica - and Lhasa to give their perspectives on this topic. This article details the top 20 take away points from the workshop for quick and easy consumption - enjoy!
05 August 2021
The top 5 benefits of data sharing with Vitic [an infographic]
08 April 2021
Working together to address the potential presence of nitrosamine impurities in medications
25 January 2021

Recent News

Lhasa Limited release new data to AI/PDE project users
New PDE data is released into the AI/PDE database.
23 September 2021

Recent Blog Articles

How to make mutagenicity assessment a simpler task
A key requirement of ICH M7 is to use two complementary (Q)SAR methodologies, one expert rule-based and the second statistical-based. This blog article recognises the benefits provided when in silico systems are integrated to provide a full ICH M7 assessment in one environment.

Discover how Lhasa Limited can help make mutagenicity assessment a simpler task, in this article!
15 September 2021

Recent Publications

In Silico Prediction of Genotoxicity Current Applications and Future Perspectives
September 2021Derek NexusSarah Nexus
Resolving conflicted data sources to a single call in Sarah Nexus [an infographic]
September 2021Sarah Nexus
Zeneth Member Type Infographic
August 2021Zeneth

Upcoming Events

Virtual Conference: EUROTOX 2021
Sep 27 2021
Virtual Conference: 2021 ACT - 42nd Annual Meeting
Nov 14 2021

Recent News

Lhasa Limited release new data to AI/PDE project users
New PDE data is released into the AI/PDE database.
23 September 2021
Lhasa Limited releases Nexus 2.4 with enhanced ICH M7 expert review support
22 July 2021
Lhasa Limited releases new data to it's Nitrites in Excipients project users
04 June 2021

Recent Blog Articles

How to make mutagenicity assessment a simpler task
A key requirement of ICH M7 is to use two complementary (Q)SAR methodologies, one expert rule-based and the second statistical-based. This blog article recognises the benefits provided when in silico systems are integrated to provide a full ICH M7 assessment in one environment.

Discover how Lhasa Limited can help make mutagenicity assessment a simpler task, in this article!
15 September 2021
Shaping Lhasa Limited’s scientific direction through collaboration
09 September 2021
A day in the life of a Marketing Executive at Lhasa Limited
23 August 2021

Archive

This is a library of Lhasa's blog articles.

5 minutes
The Application of Adverse Outcome Pathways (AOPs) for Risk Assessment (A Webinar Summary)
AOPs have the potential to be very powerful for the contextualisation of alternative assays and consequently for the management of alternative testing strategies. Read about what Lhasa is doing in this area in this blog piece written by Alun Myden, Senior Scientist at Lhasa.
- Science
03 July 2020

Sitemap

© 2021 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.